Syndax Pharmaceuticals, Inc. (SNDX) Presents at UBS Global Healthcare Conference 2025 TranscriptSeeking Alpha • 11/10/25
Syndax Pharmaceuticals: Thesis Firing On All Cylinders, Sales Acceleration In 2026Seeking Alpha • 11/05/25
Syndax Pharmaceuticals (SNDX) Reports Q3 Loss, Lags Revenue EstimatesZacks Investment Research • 11/04/25
Syndax Reports Third Quarter 2025 Financial Results and Provides Business UpdateGlobeNewsWire • 11/03/25
Syndax Announces Compelling Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr) Data Accepted for Presentation at ASH 2025GlobeNewsWire • 11/03/25
Syndax to Host ASH Investor Event in Person and via Webcast on December 8, 2025GlobeNewsWire • 11/03/25
Syndax to Announce Third Quarter 2025 Financial Results and Host Conference Call and Webcast on November 3, 2025GlobeNewsWire • 10/27/25
Syndax Pharmaceuticals, Inc. (SNDX) Discusses FDA Approval of Revuforj for Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia TranscriptSeeking Alpha • 10/25/25
Syndax Announces FDA Approval of Revuforj® (revumenib) in Adult and Pediatric Patients with Relapsed or Refractory NPM1 Mutated Acute Myeloid LeukemiaGlobeNewsWire • 10/24/25
Syndax's Revuforj® (revumenib) Included in NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for the Treatment of Relapsed or Refractory NPM1 Mutated Acute Myeloid LeukemiaGlobeNewsWire • 09/19/25
Syndax Pharmaceuticals: Revumenib PDUFA Review mNPM1 AML And Move Towards MSS CRCSeeking Alpha • 09/10/25
Syndax Pharmaceuticals, Inc. (SNDX) Presents At Citi's Biopharma Back To School Conference TranscriptSeeking Alpha • 09/02/25
Wall Street Analysts Believe Syndax (SNDX) Could Rally 112.8%: Here's is How to TradeZacks Investment Research • 09/01/25
Does Syndax (SNDX) Have the Potential to Rally 158.36% as Wall Street Analysts Expect?Zacks Investment Research • 08/14/25
Syndax Pharmaceuticals (SNDX) Reports Q2 Loss, Beats Revenue EstimatesZacks Investment Research • 08/04/25
Syndax Reports Second Quarter 2025 Financial Results and Provides Business UpdateGlobeNewsWire • 08/04/25